Treatment schedules for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 5, 2016, Pages

  Li, Emily ^a   Donati, Simone ^b   Virgili, Gianni ^c   Krzystolik, Magdalena G ^d  

^a Signature Healthcare Brockton Hospital   (United States)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d Retina Consultants   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR;

AGE RELATED MACULAR DEGENERATION; ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DATA ANALYSIS; DATA EXTRACTION; DATA SYNTHESIS; DRUG EFFECT; FOLLOW UP; HUMAN; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); VISUAL ACUITY;

EID: 84969980305     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD012208     Document Type: Article

References (51)

1. Harper RA. Chronic visual loss. Basic Ophthalmology. 9th Edition. American Academy of Ophthalmology, 2010:47-71.
2. American Academy of Ophthalmology. Age-related macular degeneration. eyewiki.aao.org/Age-related_macular_degeneration (accessed 1 September 2015).
3. Abedi F, Wickremasinghe W, Islam AFM, Inglis KM, Guymer RH. Anti-VEGF treatment in neovascular age-related macular degeneration. Retina 2014;34(8):1531-8.
4. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116(1):57-65.
5. Bourne RR, Jonas JB, Flaxman SR, Keeffe J, Leasher J, Naidoo K, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010. British Journal of Ophthalmology 2014;98(5):629-38.
6. Bressler SB. Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology 2009;116(10 Suppl):S1-7.
7. Brown GC, Brown MM, Sharma S, Stein JD, Roth Z, Campanella J, et al. The burden of age-related macular degeneration: a value-based medicine analysis. Transactions of the American Ophthalmological Society 2005;103:173-84.
8. Brown MM, Brown GC, Sharma S, Stein JD, Roth Z, Campanella J, et al. The burden of age-related macular degeneration: a value-based analysis. Current Opinion in Ophthalmology 2006;17(3):257-66.
9. Casten RJ, Rovner BW, Tasman W. Age-related macular degeneration and depression: a review of recent research. Current Opinion in Ophthalmology 2004;15(3):181-3.
10. Comparison of Age-Related Macular Degeneration Treatments Trial (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119(7):1388-98.
11. Christen WG, Glynn RJ, Manson JE, Ajani UA, Buring JE. A prospective study of cigarette smoking and risk of age-related macular degeneration in men. JAMA 1996;276(14):1147-51.
12. Heier JS, Boyer D, Nguyen QD, Marcus D, Roth DB, Yancopoulos G, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 2011;118(6):1098-106.
13. Evans JR, Fletcher AE, Wormald RP. 28, 000 cases of age-related macular degeneration causing visual loss in people aged 75 years and above in the United Kingdom may be attributable to smoking. British Journal of Ophthalmology 2005;89(5):550-3.
14. Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingermann RO, Axer-Siegel R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE Study. Ophthalmology 2011;118(5):831-9.
15. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews 2004;25(4):581-611.
16. Fiske A, Wetherell JL, Gatz M. Depression in older adults. Annual Review of Clinical Psychology 2009;5:363-89.
17. Friberg TR, Bilonick RA, Brennen PM. Risk factors for conversion to neovascular age-related macular degeneration based on longitudinal morphologic and visual acuity data. Ophthalmology 2012;119(7):1432-7.
18. Friedman DS, Katz J, Bressler NM, Rahmani B, Tielsch JM. Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey. Ophthalmology 1999;106(6):1049-55.
19. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, et al. Prevalence of age-related macular degeneration in the United States. Archives of Ophthalmology 2004;122(4):564-72.
20. Kodjikian L, Souied EH, Mimoun G, Mauget-Faysse M, Behar-Cohen F, Decullier E, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL non-inferiority randomized trial. Ophthalmology 2013;120(11):2300-9.
21. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
22. GRADEpro GDT. GRADEpro Guideline Development Tool [Software]. McMaster University, 2015 (developed by Evidence Prime, Inc.). Available from www.gradepro.org.
23. Gunda V, Sudhakar YA. Regulation of tumor angiogenesis and choroidal neovascularization by endogenous angioinhibitors. Journal of Cancer Science and Therapy 2013;5(12):417-26.
24. Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA, Li Z, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2014;121(11):2181-92.
25. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
26. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
27. Inhibition of VEGF in Age-related choroidal Neovascularization (IVAN) Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119(7):1399-411.
28. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99(6):933-43.
29. Leibowitz HM, Krueger DE, Maunder LR, Milton RC, Kini MM, Kahn HA, et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Survey of Ophthalmology 1980;24(Suppl):335-610.
30. Krebs I, Schmetterer L, Boltz A, Told R, Vecsei-Marlovits V, Egger S, et al. A randomized double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. British Journal of Ophthalmology 2013;97(3):266-71.
31. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. The New England Journal of Medicine 2006;355(14):1419-31.
32. Miller JW. Age-related macular degeneration revisited--Piecing the puzzle: The LXIX Edward Jackson memorial lecture. American Journal of Ophthalmology 2013;155(1):1-35.
33. Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD011230.pub2]
34. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. American Journal of Ophthalmology 2010;150(3):315-24.
35. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. American Journal of Ophthalmology 2009;148(1):43-58.
36. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
37. Sarwar S, Clearfield E, Soliman MK, Sadiq MA, Baldwin AJ, Hanout M, et al. Aflibercept for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2016, Issue 2. [DOI: 10.1002/14651858.CD011346.pub2]
38. Schmucker CM, Rucker G, Sommer H, Virgili G, Loke YK, Oeller P, et al. Treatment as required versus regular monthly treatment in the management of neovascular age-related macular degeneration: a systematic review and meta-analysis. PLOS One 2015;10(9):e0137866.
39. Silva R, Axer-Siegel R, Eldem B, Guymer R, Kirchhof B, Papp A, et al. The SECURE Study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology 2013;120(1):130-9.
40. Seddon JM, Willett WC, Speizer FE, Hankinson SE. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA 1996;276(14):1141-6.
41. Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2014, Issue 8. [DOI: 10.1002/14651858.CD005139.pub3]
42. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingermann RO, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011;118(4):663-71.
43. Swaroop A, Branham KEH, Chen W, Abecasis G. Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits. Human Molecular Genetics 2007;16(R2):R174-82.
44. Systematic Review Data Repository. srdr.ahrq.gov/.
45. Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Archives of Ophthalmology 2001;119(2):198-207.
46. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119(12):2537-48.
47. Verteporfin In Photodynamic (VIP) Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. American Journal of Ophthalmology 2001;131(5):541-60.
48. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113(9):1508.e1-25.
49. World Health Organization. Causes of blindness and visual impairment. Available at http://www.who.int/blindness/causes/en/ (assessed 19 April 2016).
50. Wormald R, Evans JR, Smeeth LL, Henshaw KS. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD002030.pub3]
51. Yonekawa Y, Miller JW, Kim IK. Age-related macular degeneration: advances in management and diagnosis. Journal of Clinical Medicine 2015;4(2):343-59.